Skip to main content

Table 6 Explorative baseline analysis of potential risk factors between patients with or without atherosclerotic plaques a

From: Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events

Characteristic

SSc (n = 90)

SLE (n = 100)

With plaque

Without plaque

P value

With plaque

Without plaque

P value

(n = 59)

(n = 31)

 

(n = 49)

(n = 51)

 

Age (years)

63.9 ± 12.0

45.9 ± 10.9

<0.001

57.7 ± 10.6

39.0 ± 13.0

<0.001

Male sex

10 (16.9%)

2 (6.5%)

0.206

11 (22.4%)

2 (3.9%)

0.007

Postmenopausal status, women only

44/49 (89.8%)

12/29 (41.4%)

<0.001

31/38 (81.6%)

16/49 (32.7%)

<0.001

Hypertension

38 (64.4%)

7 (22.6%)

<0.001

39 (79.6%)

17 (33.3%)

<0.001

Nicotine pack-years

13.9 ± 22.5

4.1 ± 7.8

0.003

14.7 ± 20.6

6.2 ± 8.9

0.009

Dyslipidemia

30 (50.8%)

7 (22.6%)

0.010

24 (49%)

15 (29.4%)

0.045

Age at diagnosis (years)

56.0 ± 14.3

38.7 ± 10.9

<0.001

50.8 ± 14.4

33.4 ± 11.4

<0.001

Pulmonary hypertension

15 (25.4%)

2 (6.5%)

0.045

3 (6.1%)

0 (0%)

0.114

Coronary heart disease

8 (13.6%)

2 (6.5%)

0.484

9 (18.4%)

0 (0%)

0.001

Glomerular filtration rate

85.1 ± 19.7

101.3 ± 13.4

<0.001

89.0 ± 23.1

100.6 ± 24.3

0.019

Autoantibodies

      

 SCL70

12 (20.3%)

14 (45.2%)

0.014

–

–

–

 Centromere

28 (47.5%)

8 (25.8%)

0.046

–

–

–

 ssDNA

–

–

–

10 (20.4%)

19 (37.3%)

0.063

 dsDNA

–

–

–

11 (22.4%)

27 (52.9%)

0.002

 Nucleosomes

–

–

–

7 (14.3%)

15 (29.4%)

0.068

 RNP

–

–

–

4 (8.2%)

11 (21.6%)

0.092

Immunosuppressive treatment:

      

 Duration of CS use (months)

37.2 ± 61.6

13.1 ± 29.8

0.016

25.1 ± 41.8

25.4 ± 57.0

0.978

 Cumulative CS dose (g)

8.0 ± 14.8

2.7 ± 7.5

0.030

7.5 ± 16.9

4.8 ± 8.3

0.335

 Duration of AZA use (months)

10.0 ± 29.6

7.9 ± 27.7

0.747

21.8 ± 50.5

7.7 ± 25.2

0.086

 Cumulative AZA dose (g)

29.4 ± 83.0

23.7 ± 83.0

0.763

83.9 ± 244.6

25.1 ± 79.6

0.115

  1. Values presented as number of patients (percentage) or mean ± standard deviation.
  2. AZA, azathioprine; CS, corticosteroid; dsDNA, double-stranded DNA; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; ssDNA, single-stranded DNA.
  3. aOnly variables suggested for logistic regression analysis are reported; complete report available in Additional file 2.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us